Stifel stays Buy rated on MapLight Therapeutics (MPLT) after in-line Q4 update
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $28.00 price target on MapLight Therapeutics (NASDAQ: MPLT)The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
